| From Tuesday's close, the D. Boral Capital and Maxim Group targets project a potential upside of over 1,500% and 1,100%, respectively.
On top of those, Zacks Research provided MDCX with an "Upgrade" a few months ago.
From current chart levels, do these targets and upgrade signal (Nasdaq: MDCX) to be undervalued?
#3. Medicus Advances Clinical Precision Through Strategic Collaboration With Reliant AI.
Medicus Pharma Ltd. announced a non-binding LOI with Reliant AI to build an advanced, AI-driven clinical data analytics platform enhancing the efficiency of Teverelix’s development for prostate cancer and acute urinary retention—an estimated $6Bn market.
The collaboration leverages Reliant’s generative AI and Medicus’ proprietary datasets to streamline trial execution, patient stratification, and site selection.
This step strengthens Medicus’ data-driven clinical strategy, reinforcing its commitment to cost-efficient innovation and precision-guided development as it prepares for next-stage Teverelix trials in 2026 and beyond.
#4. Medicus Achieves Milestone Advancing Non-Invasive Skin Cancer Treatment Innovation Globally.
Medicus Pharma Ltd. has completed enrollment of 90 patients in its U.S.-based Phase 2 clinical study (SKNJCT-003) evaluating the Doxorubicin Microneedle Array (D-MNA) for non-invasive treatment of basal cell carcinoma (BCC).
Conducted across nine sites, the trial marks a key step toward introducing a patient-friendly, localized immune therapy for a potential $2Bn market.
Topline results are expected in Q1 2026, with an FDA End-of-Phase 2 meeting planned soon after—underscoring Medicus’ steady progress and commitment to advancing innovative, accessible cancer care solutions.
#5. Medicus Expands Clinical Reach With Full United Kingdom Study Approvals Secured.
Medicus Pharma Ltd. has received full regulatory and ethical approvals from the UK’s MHRA, HRA, and WREC to expand its Phase 2 clinical study (SKNJCT-003) for non-invasive treatment of basal cell carcinoma (BCC).
This expansion strengthens Medicus’ international clinical footprint, enabling broader patient recruitment and a richer global dataset.
With programs now active across the U.S., Europe, and the Middle East, Medicus advances toward a pivotal study and reinforces its mission to deliver accessible, next-generation cancer care solutions worldwide. -----
Coverage is officially underway on Medicus Pharma Ltd. (Nasdaq: MDCX).
Updates will be on the way shortly. Keep your eyes peeled. All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/23/2025 and ending on 12/24/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid six thousand eight hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifty one thousand three hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-dcluk/#details | 
